Phase II study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first-line therapy in patients with non-resectable gastric cancer

Epirubicin, cisplatin and continuous infusion of 5-FU is a widely used palliative regimen in patients with gastric cancer. If cisplatin is substituted by oxaliplatin and 5-FU by capecitabine this regimen can be administered in the outpatient setting. Dose-limiting toxicity of oxaliplatin is peripher...

Descripción completa

Detalles Bibliográficos
Autores principales: Schønnemann, K R, Jensen, H A, Yilmaz, M, Jensen, B V, Larsen, O, Pfeiffer, P
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538753/
https://www.ncbi.nlm.nih.gov/pubmed/19238627
http://dx.doi.org/10.1038/sj.bjc.6604569

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538753/
https://www.ncbi.nlm.nih.gov/pubmed/19238627
http://dx.doi.org/10.1038/sj.bjc.6604569

Ejemplares similares